

## Lipigon Q1 2023 - Preparing for Phase II

Redeye comments on Lipigon's first-quarter report. After the end of Q1, all patients in the phase I study of Lipisense have been treated without any serious adverse events. The data is being analysed at the same time as a phase IIa study is being planned towards the end of the year.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Lipigon Q1 2023 - Preparing for Phase II](#)